Tilray Portugal exports first-ever shipment of medical cannabis allowed into Israel. Tilray Portugal signs 2.5 tonne strategic partnership agreement with Canndoc to address growing demand for medical cannabis products in Israeli market.
Tilray is a global pioneer in cannabis research, cultivation, production and distribution. The company announced that has entered into an agreement with Canndoc, through its wholly-owned subsidiary Tilray Portugal, to export a wholesale shipment of up to 2.5 tonnes of medical cannabis from Portugal to Israel. The shipment is the first medical cannabis import allowed into Israel.
“We’re incredibly honored to partner with Canndoc to help increase patient access in Israel while becoming the first to ship medical cannabis into the country for commercial use. Israel represents our fifteenth export country and the second shipment from our EU Campus in Cantanhede, Portugal”, said Brendan Kennedy, Tilray’s Chief Executive Officer.
Tilray also announced an agreement to export first shipment of $3.3 million worth of medical cannabis from Portugal to Germany.
In addition, the company has signed a Definitive Agreement with Esporão, adding 20 hectares of outdoor cultivation space in Alentejo, Portugal. Not to mention the existing 5 hectares of indoor and outdoor cultivation and 6,500 square meters of manufacturing, processing and research space at its European Union (EU) Campus in Cantanhede, Portugal.
Tilray, which has invested $20 million to enter the European market, plans to expand in the coming months. The company is currently exporting its products manufactured in Portugal to several European Union countries, such as Germany, Ireland, the United Kingdom, Croatia, and Cyprus. Tilray now exports medical cannabis to 15 countries worldwide.
Source: TILRAY, AICEP, JORNAL DE NEGÓCIOS
